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Hypoxic myoclonic status
PerampanelProper treatment of hypoxic myoclonic status is not clearly determined. Induced hypothermia is improving
prognosis and a more aggressive treatment might be beneﬁcial in some patients. Among the new options of
antiepileptic drugs, perampanel (PER) is a drugwith a novelmechanism, and itmight be a promising drug formyo-
clonic status or as an antimyoclonic drug. We describe the use of PER in one patient with hypoxic super-refractory
myoclonic status.
Description: A 51-year-old patient presented after an out-of-hospital cardiac arrest due to an acute myocardial
infarction. The patient was diagnosed with clinical and electrical (EEG) myoclonic status at the rewarming
phase. Several treatments were used, starting with clonazepam, valproate, sedation (midazolam, propofol), and
subsequently barbiturate-induced coma with persistent myoclonic status. Finally, we decided to try PER (dose:
6–8mg) through a nasogastric tube, resulting in amarked improvement of EEG activity andmyoclonus decrease.
The patient had a progressive clinical improvement, with a CPC (Cerebral Performance Category) scale score of 1.
Conclusion: This case shows the potential utility of PER as a therapeutic option in super-refractory hypoxic status
and even its potential use before other aggressive alternatives considering their greater morbidity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The intensity of treatment of postanoxic myoclonic status is not
clearly established: it can be considered that myoclonic status is only a
marker of the severity of the initial damage and therefore its treatment
does not improve the prognosis; however, other authors point out that
status epilepticus (SE) acts actively to increase brain injury and worsen
prognosis, so its aggressive treatment could improve prognosis [1].
The introduction of therapeutic hypothermia is improving the prog-
nosis of these patients, and there is an increasing number of new studies
and reassessment of concepts in hypoxic encephalopathy. Aggressive
treatment could be justiﬁed in some patients since they may awaken
if their seizures are treated adequately. Treatment in these cases is
usually initiated in a similar way to any SE but with particularities:
clonazepam, valproate, levetiracetam, or piracetam is preferable to
other antiepileptic drugs (AEDs) (especially phenytoin) due to their
antimyoclonic action, and, if necessary, the comatose state should bet of Neurology, Hospital Vall d'
na).
. This is an open access article underinduced pharmacologically, controlling the depth of coma by EEG until
epileptiform activity is eliminated.
In many centers, the treatment of postanoxic myoclonic status
includes all these options (levetiracetam, valproate, midazolam, and
propofol) for a minimum of 24 h, and then between 24 and 72 h, the
treatment is reassessed according to the patient's condition based on
brainstem reﬂexes and/or cortical response (N20 wave) to somatosen-
sory-evoked potentials.
Among the new options in AEDs, perampanel (PER) constitutes a
drug with a novel mechanism of action that makes it attractive for
use in situations of SE. We report the ﬁrst case, to our knowledge,
of a patient with postanoxic myoclonic status super-refractory to
all antiepileptic drugs and sedatives used, in whom the efﬁcacy of
PER was tested.
2. Case report
A 51-year-old male patient presented after an out-of-hospital car-
diorespiratory arrest in the context of an anterolateral acute myocardial
infarction (AMI) — Killip class II. The patient's history included only
active smoking without other cardiovascular risk factors. Cardiopul-
monary resuscitation (CPR) maneuvers were performed for 15 minthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. EEG evolution before PER. (a) 12 h post-CPR. Hypothermia (33 °C). Sedation with midazolam and morphine chloride. Burst-suppression pattern. Pectoral and laterocervical
myoclonia. (b) 72 h post-CPR. Sedation. AEDs: CZP, VPA. Spiky bilateral periodic discharges. Bipolar montage (sensitivity: 15 μV/mm; speed: 20 s). CPR: cardiopulmonary resuscitation.
AED: antiepileptic drug. CZP: clonazepam. VPA: valproic acid.
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hospital, the hypothermia protocol was initiated to target a body
temperature of 33 °C. A coronary arteriography was subsequently
performed with revascularization of the occluded vessel.Twelve hours after CPR (still in the hypothermia phase), the patient
was observed to have early myoclonic SE with a burst-suppression EEG
pattern (Fig. 1a). Despite the introduction of clonazepam and valproic
acid (40 mg/kg), electroclinical worsening was observed in the
58 E. Santamarina et al. / Epilepsy & Behavior Case Reports 4 (2015) 56–59followinghours (rewarming phase), with intense spiky bilateral period-
ic activity on the EEG and increase inmyoclonic jerks (Fig. 1b), and leve-
tiracetam (40 mg/kg) was added. The EEG acquired an alternating
pattern with persistence of spiky activity and myoclonic jerks (mainlyFig. 2. EEG after administration of PER. No sedation. AEDs: PER, 8 mg/24 h; LEV, 1500 mg/12 h
montage (sensitivity: 15 μV/mm; speed: 20 s). (b) Spike–waves in parietal and occipital reg
stimulation. Referential (common average) montage (sensitivity: 10 μV/mm; speed: 20 s). AEDfacial), and it was therefore decided to increase the degree of sedation
with midazolam and propofol. The patient had brainstem reﬂexes and
response to nociceptive stimulus. Despite high dose sedation, total re-
mission of the myoclonic state was not achieved, and after a week, a; CZP, 0.5 mg/8 h. (a) 8-Hz alpha rhythms and spike–waves in posterior regions. Bipolar
ions. Reactivity present with greater synchronization of background activity to acoustic
: antiepileptic drug. PER: perampanel, CZP: clonazepam, LEV: levetiracetam.
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after lowering the doses of barbiturate; therefore, we decided to admin-
ister perampanel via a nasogastric tube at an initial dose of 6 mg and
then 8 mg, with signiﬁcant clinical and electrical improvement.
The EEG showed recovery of background activity with hyporeactive
8-Hz alpha rhythms and isolated spike–waves focalized in the posterior
regions of both hemispheres; no myoclonia was identiﬁed (Fig. 2a
and b). This new situation allowed us to start withdrawal of sedation
with clonazepam and to lower the doses of the other AEDs. This was as-
sociated clinically with progressive recovery of level of consciousness
with the patient connecting to his surroundings and responding to
questions coherently. The ﬁnal CPC (Cerebral Performance Category)
scale score was 1.
The cranial MRI did not show acute or subacute ischemic lesions on
the diffusion study nor any other type of signal alterations in cerebral or
cerebellar parenchyma.
Treatment with PER was maintained for 10 days with no recurrence
of myoclonia, and the other antiepileptic medications (valproate,
levetiracetam) were withdrawn without problems.
3. Discussion
To our knowledge, this is the ﬁrst reported case in the literature of a
hypoxic myoclonic SE in which perampanel was used. Few data are
available on the possible clinical utility of PER in situations of SE.
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
receptors play an important role in the initiation and propagation of
epileptic activity [2]. In animal models of SE induced by pilocarpine,
refractory SE was associated with a selective reduction of surface ex-
pression of the GluA2 subunit of the AMPA receptor on hippocampal
cell membranes and with increased internalization of this subunit [3].
This results in AMPA receptors with different biophysical characteristics
permeable to calcium and, consequently, in continuous neurotransmis-
sion. Therefore, inhibition of AMPA receptor activity could be a potential
target in the treatment of refractory SE.
Perampanel selectively blocks AMPA receptor-mediated synaptic
transmission and thus it appears to be an attractive option for these
cases. In addition, PER has shown broad-spectrum antiepilepticactivity when administered orally in preclinical animal models, in-
cluding antimyoclonic activity [4]. These data therefore suggest its
potential utility in hypoxic SE.
The aggressive approach to treatment in this patient was based on
preservation of brainstem reﬂexes in the neurological examination
and on the presence of early reactivity on EEG recordings followed by
a progressive recovery of background activity, as recommended by
some authors [1]. The lack of response after administering different
AEDs and sedation including barbiturates led us to consider a drug
with a different mechanism of action.
It is difﬁcult to demonstratewith a single case the relationship of the
drug to cessation of antiepileptic activity, but there seems to be no other
explanation in this patient since even the barbiturate had been
discontinued before the introduction of PER.
This case shows the potential utility of PER in these dramatic situa-
tions and even its potential use before other aggressive alternatives con-
sidering their greater morbidity (with prolongation of hospitalization
and days requiring intubation).Disclosures
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